Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Familial Hypercholesterolemia (ARCHITECT)
NCT05465278Phase 4Completed
- Sponsor
- Fundación Hipercolesterolemia Familiar
- Start
- May 2018
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in familial hypercholesterolemia (FH), sponsored by Fundación Hipercolesterolemia Familiar. Primary endpoint: Change in percentage of volume of atheroma at 18 months. Started May 2018; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT05465278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05465278.